A Phase 3 trial studied liraglutide for body weight in obese subjects
Liraglutide — Evidence
Clinical trials and publications sourced from ClinicalTrials.gov, PubMed, and FDA. Updated hourly by the automated crawler.
Claims and sources (2)
A publication reported on liraglutide and cardiovascular outcomes in type 2 diabetes
Verified evidence (2)
Effect of Liraglutide on Body Weight in Obese Subjects
Phase 3 · COMPLETED · Started 2011
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
PubMed publication · Published 2016
Registered studies (50)
From the ClinicalTrials.gov record captured for this substance. Registration is not evidence of approval, efficacy, or safety.
GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial
Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery
Effects of GH and Lirglutide on AgRP
Effects of Glucagon-like-Peptide-1 Analogues on Sexuality
Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus
Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee
A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland
A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects
The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients
In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants
The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS
Saxenda in Obesity Services (STRIVE Study)
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Saxenda: Underlying Mechanisms and Clinical Outcomes
Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Loss
Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism.
A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
Treatment of Diabetic Neuropathy With Liraglutide
Evaluating Liraglutide in Alzheimer's Disease
Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting
Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines
A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin
Liraglutide and Heart Failure in Type 2 Diabetes
The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)
The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes
Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects
The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes
Study of RO6807952 in Patients With Diabetes Mellitus Type 2
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)
Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus
Comparison of Two Liraglutide Formulations in Healthy Subjects
Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes
Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers
Comparison of Two Liraglutide Formulations in Healthy Volunteers
Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes
ClinicalTrials.gov (3)
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Phase N/A · RECRUITING · Sponsor: Ohio State University
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
Phase NA · COMPLETED · Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Phase PHASE1 · RECRUITING · Sponsor: Novo Nordisk A/S
PubMed (21)
Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications.
Journal of diabetes investigation · 2026 Jul 25 · DOI: 10.1111/jdi.70407
Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.
British journal of clinical pharmacology · 2026 Jul 16 · DOI: 10.1002/bcp.70711
Circulating levels of PYY are increased in individuals with bile acid diarrhoea.
The Journal of clinical endocrinology and metabolism · 2026 Jul 24 · DOI: 10.1210/clinem/dgag295
Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis.
Schizophrenia research · 2026 Jul 24 · DOI: 10.1016/j.schres.2026.06.025
Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism.
Nature metabolism · 2026 Jul 24 · DOI: 10.1038/s42255-026-01575-z
Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications.
Journal of diabetes investigation · 2026 Jul 25 · DOI: 10.1111/jdi.70407
Comparative effectiveness of Chinese herbal medicine versus liraglutide for weight loss in adults with obesity: A 12-month real-world target trial emulation study.
Integrative medicine research · 2026 Sep · DOI: 10.1016/j.imr.2026.101291
Synergistic cardioprotection by liraglutide and deferoxamine against doxorubicin-induced cardiotoxicity via modulation of ACSL-4/Nrf-2/GPX-4 signaling.
Naunyn-Schmiedeberg's archives of pharmacology · 2026 Jul 18 · DOI: 10.1007/s00210-026-05646-6
GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence.
Multiple sclerosis and related disorders · 2026 Jul 10 · DOI: 10.1016/j.msard.2026.107388
Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.
Annals of the American Thoracic Society · 2026 Jul 21 · DOI: 10.1093/annalsats/aaoag177
A systematic review and meta-analyses of glucagon-like peptide-1 receptor agonists in acute myocardial infarction.
The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026 Jul 21 · DOI: 10.1186/s43044-026-00767-y
GLP-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From rats to humans.
Biological psychiatry · 2026 Jul 21 · DOI: 10.1016/j.biopsych.2026.06.033
Safety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation.
Diabetes, obesity & metabolism · 2026 Jul 21 · DOI: 10.1111/dom.71138
Glucagon-Like Peptide-1 Receptor Agonists in Orthopedics: A Scoping Review of Emerging Applications.
Indian journal of orthopaedics · 2026 Jul · DOI: 10.1007/s43465-025-01614-z
Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations.
The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2026 Jul 20 · DOI: 10.1177/87551225261466571
Weight Loss Following Liraglutide Therapy in a Patient With Smith-Magenis Syndrome: A Case Report.
Cureus · 2026 Jun · DOI: 10.7759/cureus.111313
GLP-1 receptor agonists in Parkinson's disease: a meta-analysis revealing motor benefit and highlighting mood improvement.
Frontiers in neurology · 2026 · DOI: 10.3389/fneur.2026.1858507
Clinical efficacy of liraglutide combined with pioglitazone in obese polycystic ovary syndrome and its effects on the serum chemerin/visfatin ratio.
American journal of translational research · 2026 · DOI: 10.62347/WNDZ4386
A survey of primary care physicians' views on supporting patients who lose insurance coverage for Glucagon-Like Peptide-1-based drugs for weight management.
Obesity pillars · 2026 Sep · DOI: 10.1016/j.obpill.2026.100304
Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.
Cureus · 2026 Jun · DOI: 10.7759/cureus.111363
Circulating levels of PYY are increased in individuals with bile acid diarrhoea.
The Journal of clinical endocrinology and metabolism · 2026 Jul 24 · DOI: 10.1210/clinem/dgag295